Active, not recruitingPhase 2NCT05241340

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Studying Muscular tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Methodist Hospital Research Institute
Principal Investigator
Raj Satkunasivam, MD
Houston Methodist Hospital, Houston Methodist Research Institute
Intervention
Sasanlimab(drug)
Enrollment
33 enrolled
Eligibility
18 years · All sexes
Timeline
20222027

Study locations (1)

Collaborators

Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05241340 on ClinicalTrials.gov

Other trials for Muscular tumor

Additional recruiting or active studies for the same condition.

See all trials for Muscular tumor

← Back to all trials